Thursday, August 28, 2014

Prestige Brands Holdings Inc , which markets and distributes healthcare and cleaning products, has won U.S. antitrust approval to purchase Insight Pharmaceuticals Corp on condition that it divest a motion-sickness drug, the Federal Trade Commission said on Thursday. Prestige, known for its Dramamine motion sickness pills and Massengill feminine hygiene products, said in April that it would buy Insight for $750 million. Insight also sells EPT home pregnancy tests and Uristat urinary health products, among others.Prestige agreed to divest the over-the-counter motion sickness drug Bonine in order to win antitrust approval for the deal, the FTC said in a statement. Dramamine and Bonine are the only two name brand motion sickness drugs with significant sales, the FTC said.Wellspring Pharmaceuticals has agreed to buy Bonine, the FTC said.Prestige, whose growth has mainly been powered by acquisitions, bought the Dramamine brand in the United States in January 2011 and a year later purchased 17 North American OTC healthcare brands from GlaxoSmithKline Plc.

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Shares of GSK traded higher by 0.41% or $0.2/share to $48.87. In the past year, the shares have traded as low as $46.01 and as high as $56.73. On average, 3111470 shares of GSK exchange hands on a given day and today's volume is recorded at 2648461.

Prestige Brands Holdings, Inc. (Prestige) is a holding company. Shares of PBH fell by 1.28% or $-0.45/share to $34.75. In the past year, the shares have traded as low as $24.94 and as high as $36.69. On average, 266322 shares of PBH exchange hands on a given day and today's volume is recorded at 134885.

Please Donate

Article Archive

The reports on this site are for information purposes only and are not a recommendation for the purchase of securities. The information contained in these reports have been gathered from sources we believe to be reliable, however, we make no guarantee as to the accuracy or completeness to such information.